Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

O Mosenzon, SD Wiviott, A Cahn… - The lancet Diabetes & …, 2019 - thelancet.com
Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial
effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular …
被引用次数：687 相关文章

[引用][C] Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised …

O Mosenzon, SD Wiviott, A Cahn, A Rozenberg… - The Lancet Diabetes …, 2019 - elibrary.ru

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

O Mosenzon, SD Wiviott… - The Lancet …, 2019 - utsouthwestern.elsevierpure.com
Background: Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial
effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular …

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial

O Mosenzon, SD Wiviott, A Cahn… - Lancet Diabetes & …, 2019 - research.rug.nl
Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial
effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular …

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial

O Mosenzon, SD Wiviott, A Cahn, A Rozenberg… - 2019 - pubmed.ncbi.nlm.nih.gov
Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial
effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular …

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.

O Mosenzon, SD Wiviott, A Cahn… - The lancet. Diabetes …, 2019 - europepmc.org
Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial
effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular …

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

O Mosenzon, SD Wiviott, A Cahn, A Rozenberg… - The Lancet Diabetes & …, 2019 - Elsevier
Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial
effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular …

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: ananalysis from the DECLARE–TIMI 58 randomised trial

O Mosenzon, SD Wiviott, A Cahn, A Rozenberg… - 2019 - thelancet.com
Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial
effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular …

[引用][C] Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised …

O Mosenzon, SD Wiviott, A Cahn… - The Lancet Diabetes & …, 2019 - cir.nii.ac.jp
Effects of dapagliflozin on development and progression of kidney disease in patients with
type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial | CiNii Research …

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

O Mosenzon, SD Wiviott, A Cahn, A Rozenberg… - The Lancet Diabetes & …, 2019 - Elsevier
Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial
effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular …